These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 11316859)
41. Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice. Pierzynowska K; Deshpande A; Mosiichuk N; Terkeltaub R; Szczurek P; Salido E; Pierzynowski S; Grujic D Front Med (Lausanne); 2020; 7():569215. PubMed ID: 33330529 [TBL] [Abstract][Full Text] [Related]
42. Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant. Zhang C; Fan K; Luo H; Ma X; Liu R; Yang L; Hu C; Chen Z; Min Z; Wei D Int J Pharm; 2012 Jul; 430(1-2):307-17. PubMed ID: 22503989 [TBL] [Abstract][Full Text] [Related]
43. Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase. Tsuji J; Hirose K; Kasahara E; Naitoh M; Yamamoto I Int J Immunopharmacol; 1985; 7(5):725-30. PubMed ID: 2412977 [TBL] [Abstract][Full Text] [Related]
44. Pharmacodynamic analysis of intravenous recombinant urate oxidase using an indirect pharmacological response model in healthy subjects. Cai NF; Cheng ZN; Zi Y; Luo X; Guo X; Liu Z; Zheng LY Acta Pharmacol Sin; 2014 Nov; 35(11):1447-52. PubMed ID: 25283504 [TBL] [Abstract][Full Text] [Related]
45. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852 [TBL] [Abstract][Full Text] [Related]
46. Pegloticase and lowering blood pressure in refractory gout; is it uric acid or hydrogen peroxide? Fini MA; Stenmark KR Eur J Intern Med; 2019 Nov; 69():e11-e12. PubMed ID: 31471165 [No Abstract] [Full Text] [Related]
48. Novel drug discovery strategies for gout. Richette P; Garay R Expert Opin Drug Discov; 2013 Feb; 8(2):183-9. PubMed ID: 23231400 [TBL] [Abstract][Full Text] [Related]
49. Uricase-deficient rats with similarly stable serum uric acid to human's are sensitive model animals for studying hyperuricemia. Gao Y; Yu Y; Qin W; Fan N; Qi Y; Chen H; Duan W PLoS One; 2022; 17(3):e0264696. PubMed ID: 35239728 [TBL] [Abstract][Full Text] [Related]
50. Modification with polysialic acid-PEG copolymer as a new method for improving the therapeutic efficacy of proteins. Wu J; Lu S; Zheng Z; Zhu L; Zhan X Prep Biochem Biotechnol; 2016 Nov; 46(8):788-797. PubMed ID: 26829568 [TBL] [Abstract][Full Text] [Related]
51. Pegloticase (krystexxa) for treatment of refractory gout. Med Lett Drugs Ther; 2011 Feb; 53(1357):9-10. PubMed ID: 21304442 [No Abstract] [Full Text] [Related]
52. Intestine-Targeted Explosive Hydrogel Microsphere Promotes Uric Acid Excretion for Gout Therapy. Tang Y; Du Y; Ye J; Deng L; Cui W Adv Mater; 2024 Jan; 36(3):e2310492. PubMed ID: 37997010 [TBL] [Abstract][Full Text] [Related]
53. Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase. Zhang C; Fan K; Ma X; Wei D PLoS One; 2012; 7(6):e39659. PubMed ID: 22745806 [TBL] [Abstract][Full Text] [Related]
54. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z; Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308 [TBL] [Abstract][Full Text] [Related]